The pharmaceutical industry is experiencing unprecedented M&A activity driven by urgent patent expiration concerns. Major drugmakers are aggressively acquiring biotech firms to secure innovative pipelines and combat revenue losses from generic competition. This acquisition frenzy reflects strategic pressure to identify next-generation blockbuster treatments before critical patent cliffs arrive. Companies are investing heavily in emerging therapies and cutting-edge research capabilities to maintain competitive advantage and ensure long-term profitability in an increasingly dynamic healthcare landscape.

Summary auto-generated by AI from the original publisher's content. Editorial standards.